GURUFOCUS.COM » STOCK LIST » Real Estate » REITs » Ventas Inc (NYSE:VTR) » Definitions » Sloan Ratio %

Ventas (Ventas) Sloan Ratio %

: -3.95% (As of Dec. 2023)
View and export this data going back to 1997. Start your Free Trial

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Ventas's Sloan Ratio for the quarter that ended in Dec. 2023 was -3.95%.

As of Dec. 2023, Ventas has a Sloan Ratio of -3.95%, indicating the company is in the safe zone and there is no funny business with accruals.


Ventas Sloan Ratio % Historical Data

The historical data trend for Ventas's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ventas Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.35 -4.87 -1.02 -1.28 -3.95

Ventas Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.28 -2.83 -2.46 -3.32 -3.95

Competitive Comparison

For the REIT - Healthcare Facilities subindustry, Ventas's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ventas Sloan Ratio % Distribution

For the REITs industry and Real Estate sector, Ventas's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Ventas's Sloan Ratio % falls into.



Ventas Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Ventas's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-40.973-1119.873
--184.664)/24725.433
=-3.95%

Ventas's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(-40.973-1119.873
--184.664)/24725.433
=-3.95%

Ventas's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was 17.517 (Mar. 2023 ) + 103.453 (Jun. 2023 ) + -71.124 (Sep. 2023 ) + -90.819 (Dec. 2023 ) = $-41 Mil.
Ventas's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was 242.817 (Mar. 2023 ) + 311.827 (Jun. 2023 ) + 286.145 (Sep. 2023 ) + 279.084 (Dec. 2023 ) = $1,120 Mil.
Ventas's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -56.28 (Mar. 2023 ) + -71.327 (Jun. 2023 ) + -13.781 (Sep. 2023 ) + -43.276 (Dec. 2023 ) = $-185 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ventas  (NYSE:VTR) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Ventas has a Sloan Ratio of -3.95%, indicating the company is in the safe zone and there is no funny business with accruals.


Ventas Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Ventas's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ventas (Ventas) Business Description

Traded in Other Exchanges
Address
353 North Clark Street, Suite 3300, Chicago, IL, USA, 60654
Ventas owns a diversified healthcare portfolio of nearly 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes over 40 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 3% of net operating income.
Executives
Walter C Rakowich director 14100 E 35TH PL, AURORA CO 80011
Debra A Cafaro director, officer: Chairman, President and CEO 353 N. CLARK STREET, SUITE 3300, CHICAGO IL 60654
Sumit Roy director 600 LA TERRAZA BOULEVARD, ESCONDIDO CA 92025
Michael J Embler director C/O NMI HOLDINGS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Robert D. Reed director 47 DONALD DRIVE, ORINDA CA 94563
James D Shelton director 3901 TURTLE CREEK BLVD. #12, DALLAS TX 75219
Richard I Gilchrist director 5950 SHERRY LANE, SUITE 700, DALLAS TX 75225
Robert F Probst officer: EVP, CFO and Acting CAO 353 N. CLARK STREET, SUITE 3300, CHICAGO IL 60654
Gregory R Liebbe officer: SVP, Chief Accounting Officer 500 N. HURSTBOURNE PARKWAY, SUITE 200, LOUISVILLE KY 40222
Maurice S Smith director 353 N. CLARK STREET, SUITE 3300, CHICAGO IL 60654
Marguerite M Nader director 2S601 AVENUE LA TOURS, OAK BROOK IL 60523
Carey S. Roberts officer: EVP and GC C/O VENTAS, INC., 353 N. CLARK STREET, SUITE 3300, CHICAGO IL 60654
James Justin Hutchens officer: EVP Sr Housing North America C/O VENTAS, INC., 353 N. CLARK STREET, SUITE 3300, CHICAGO IL 60654
John D. Cobb officer: SVP & Chief Investment Officer 353 N. CLARK STREET, SUITE 3300, CHICAGO IL 60654
Sean P. Nolan director C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005

Ventas (Ventas) Headlines